AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for accelerated ... making it the most common form. By the end of the year, it is estimated that there ...

AstraZeneca PLC ... to withdraw their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of lung cancer.

AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the ... on this site does not imply any form of partnership, agency, or endorsement.

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said that they have voluntarily withdrawn their marketing authorisation application (MAA) in the European ...

FDA approves AstraZeneca’s Imfinzi for limited-stage ... SCLC is a highly aggressive form of lung cancer. The FDA approval was based on results from the ADRIATIC Phase 3 trial, presented during ...

AstraZeneca's application for sipavibart has been accepted under an accelerated assessment procedure. Also Read: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion.

July 1 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 ...

and its partner Daiichi Sankyo have decided to withdraw their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of lung ...

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) ...

(Reuters) -AstraZeneca said on Monday that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, sipavibart, for an ...

LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision ...